169 related articles for article (PubMed ID: 19850405)
1. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
2. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase.
Stancato LF; Silverstein AM; Owens-Grillo JK; Chow YH; Jove R; Pratt WB
J Biol Chem; 1997 Feb; 272(7):4013-20. PubMed ID: 9020108
[TBL] [Abstract][Full Text] [Related]
3. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
Kitson RR; Moody CJ
Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.
Pezzulo AA; Tudas RA; Stewart CG; Buonfiglio LGV; Lindsay BD; Taft PJ; Gansemer ND; Zabner J
J Clin Invest; 2019 Feb; 129(2):744-758. PubMed ID: 30640172
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin confers fungicidal properties to azole by triggering the activation of succinate dehydrogenase.
Xiong J; Wang L; Feng Y; Zhen C; Hang S; Yu J; Lu H; Jiang Y
Life Sci; 2024 Jul; 348():122699. PubMed ID: 38718854
[TBL] [Abstract][Full Text] [Related]
6. Hsp90, an unlikely ally in the war on cancer.
Barrott JJ; Haystead TA
FEBS J; 2013 Mar; 280(6):1381-96. PubMed ID: 23356585
[TBL] [Abstract][Full Text] [Related]
7. Macrocyclic inhibitors of hsp90.
Johnson VA; Singh EK; Nazarova LA; Alexander LD; McAlpine SR
Curr Top Med Chem; 2010; 10(14):1380-402. PubMed ID: 20536417
[TBL] [Abstract][Full Text] [Related]
8. Heat Shock Protein 90 regulates the stability of c-Jun in HEK293 Cells.
Lu C; Chen D; Zhang Z; Fang F; Wu Y; Luo L; Yin Z
Mol Cells; 2007 Oct; 24(2):210-4. PubMed ID: 17978573
[TBL] [Abstract][Full Text] [Related]
9. Maximizing the Therapeutic Potential of HSP90 Inhibitors.
Butler LM; Ferraldeschi R; Armstrong HK; Centenera MM; Workman P
Mol Cancer Res; 2015 Nov; 13(11):1445-51. PubMed ID: 26219697
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker.
Aboagye EO
Oncotarget; 2010 Jul; 1(3):163-166. PubMed ID: 21301046
[No Abstract] [Full Text] [Related]
11. Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases.
Banerjee M; Hatial I; Keegan BM; Blagg BSJ
Pharmacol Ther; 2021 May; 221():107747. PubMed ID: 33245994
[TBL] [Abstract][Full Text] [Related]
12. Cascade Transformation of the Ansamycin Benzoquinone Core into Benzoxazole Influencing Anticancer Activity and Selectivity.
Skrzypczak N; Pyta K; Bohusz W; Leśniewska A; Gdaniec M; Ruszkowski P; Schilf W; Bartl F; Przybylski P
J Org Chem; 2023 Jul; 88(13):9469-9474. PubMed ID: 37276434
[TBL] [Abstract][Full Text] [Related]
13. Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer.
Serwetnyk MA; Crowley VM; Brackett CM; Carter TR; Elahi A; Kommalapati VK; Chadli A; Blagg BSJ
ACS Med Chem Lett; 2023 Dec; 14(12):1785-1790. PubMed ID: 38116437
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H; Zhang Y; Jia Y; Chen X; Niu T; Chatterjee A; He P; Hou G
MedComm (2020); 2024 Feb; 5(2):e470. PubMed ID: 38283176
[TBL] [Abstract][Full Text] [Related]
15. Study of interaction energies between residues of the active site of Hsp90 and geldanamycin analogues using quantum mechanics/molecular mechanics methods.
Vivas-Reyes R; Morales-Bayuelo A; Gueto C; Drosos JC; Márquez Lázaro J; Baldiris R; Ahumedo M; Vivas-Gomez C; Aparicio D
F1000Res; 2019; 8():2040. PubMed ID: 37767457
[No Abstract] [Full Text] [Related]
16.
Weeraphan T; Supong K; Sripreechasak P; Jutakanoke R; Kowinthanaphat S; Tanasupawat S; Pittayakhajonwut P; Phongsopitanun W
Antibiotics (Basel); 2023 Sep; 12(9):. PubMed ID: 37760763
[TBL] [Abstract][Full Text] [Related]
17. Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis.
Czaja AJ
Dig Dis Sci; 2023 Nov; 68(11):4098-4116. PubMed ID: 37755606
[TBL] [Abstract][Full Text] [Related]
18. Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.
Orozco Morales ML; Rinaldi CA; de Jong E; Lansley SM; Lee YCG; Zemek RM; Bosco A; Lake RA; Lesterhuis WJ
PLoS One; 2023; 18(5):e0274364. PubMed ID: 37146029
[TBL] [Abstract][Full Text] [Related]
19. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract][Full Text] [Related]
20. Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines.
Alves R; Santos D; Jorge J; Gonçalves AC; Catarino S; Girão H; Melo JB; Sarmento-Ribeiro AB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
